bioMérieux S.A.
bioMérieux S.A. (BMXMF) Stock Overview
Explore bioMérieux S.A.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
16.8B
P/E Ratio
34.78
EPS (TTM)
$4.22
ROE
0.10%
BMXMF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of bioMérieux S.A. (BMXMF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $126.77.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 34.78 and a market capitalization of 16.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Pierre Boulud
14,147
376 Chemin De l’Orme, Marcy l'Étoile
2017